Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eton Pharmaceuticals

These 3 Defensive Stocks Just Hit 52-Week Highs — Should You Lock In Gains?

High PEG ratios indicate that many defensive stocks in health care and consumer staples trade at stretched valuations. With earnings growth lagging price momentum, three stand out as candidates for profit-taking while the market’s risk appetite begins to shift.

Eton Pharma - Small Cap That's Climbing

Eton Pharma - Small Cap That's Climbing

Summary Eton Pharmaceuticals (ETON) has shown exceptional price appreciation, gaining 224.93% since a Trend Seeker buy signal on 7/17, supported by strong technical indicators. The company focuses on developing and commercializing pharmaceutical products for rare diseases, with significant revenue and earnings growth expected in the coming years. Barchart's technical indicators...

3 Pharma Stocks for January 2024 Profits

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Earnings Outlook For Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Eton Pharmaceuticals will report an earnings per share (EPS) of $-0.08.

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

Abbott Laboratories

Medical Pharmaceuticals

Novo Nordisk AS

Apellis Pharmaceuticals

Ultragenyx Pharmaceutical

Darling Ingredients

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

359,656 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play